Table 3

Baseline demographics and clinical characteristics of abatacept clinical trial patients and RA DMARD cohorts included in the epidemiological analyses

Abatacept Clinical Trial Program (N  =  4134)BC (N  =  12 337)NDB (N  =  10 499)GPRD (N  =  14 467)NOAR (N  =  523)Sweden ERA (N  =  3703)
Age, years, n (%)
    <204 (0.1)214 (2)13 (0.1)34 (0.2)3 (1)29 (1)
    20–441011 (24)2874 (23)1429 (14)2856 (20)106 (20)753 (20)
    45–642435 (59)5148 (42)4870 (47)6998 (48)246 (47)1624 (44)
    65–74553 (13)2692 (22)2716 (26)3375 (23)120 (23)797 (22)
    ⩾75131 (3)1409 (11)1438 (14)1204 (8)48 (9)500 (14)
Female, n (%)3323 (80)8936 (72)7971 (76)10 284 (71)357 (68)2589 (70)
Duration of RA, years, n (%)
    <51353 (33)4890 (40)2726 (29)*NA5233703
    5–101192 (29)4206 (34)1902 (20)*NA00
    >101586 (38)3241 (26)4716 (50)*NA00
Concomitant medications, n (%)
    Oral corticosteroids2657 (64)8121 (66)NA6902 (48)194 (37)NA
    NSAID3113 (75)11 001 (89)6820 (65)13 656 (94)416 (80)NA
Total follow-up, years
    Mean2.14.93.33.77.93.6
    Median1.86.02.54.19.3NA
  • *Rheumatoid arthritis (RA) duration was not collected for every subject in the NDB; therefore, n  =  9344 for this variable. Use of concomitant medications at baseline is presented for the abatacept trial population, whereas use during follow-up is presented for the RA cohorts (when available).

  • BC, British Columbia RA Cohort; DMARD, disease-modifying antirheumatic drug; GPRD, General Practice Research Database; NDB, National Data Bank for Rheumatic Diseases; NOAR, Norfolk Arthritis Register; NSAID, non-steroidal anti-inflammatory drugs; Sweden ERA, Sweden Early Rheumatoid Arthritis Register.